Northwestern University

northwestern.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

1,396

Active

272

Phase 3

51

Total enrollment

638,363

Pipeline matrix

Showing 40 of 116 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Prednisone10
Abiraterone Acetate2
Naproxen 500 Mg2
Dupilumab3
Methylprednisolone13
Dexamethasone4
Erythropoietin2
cabergoline2
Gadavist 2Ml Solution for1
Topical EMLA cream1
botulinum toxin A1
GnRH agonist/antagonist1
Enzalutamide1
Statin1
Misoprostol Tabets1
Morphine Sulfate1
Ublituximab1
celecoxib5
Duloxetine4
Nitrate Rich Beetroot Juice1
Valproic Acid1
Fresh Frozen Plasma1
Dronabinol1
OnabotulinumtoxinA1
cocoa flavanols1
Furosemide2
Pembrolizumab12
Pemetrexed6
Futibatinib2
Extended Release Metformin Hydrochloride2
Saline11
Alemtuzumab6
bevacizumab11
gemcitabine hydrochloride5
Gemcitabine5
fluorouracil4
cisplatin4
Durvalumab3
Afimoxifene3
Dacarbazine3
76 more active programs hidden

Next readouts

  • 2015-08-17
  • 2023-01-04
  • 2023-05-23
  • 2023-06-06
  • 2023-10-21
  • 2023-12-11
  • 2024-01-24
  • 2024-06-30
  • 2025-04-01
  • 2025-06-01

Top conditions

  • Pain46
  • Depression43
  • Breast Cancer35
  • Lymphoma29
  • Obesity27
  • Anxiety23
  • Pregnancy23
  • Cancer20

Frequently asked questions about Northwestern University

How many clinical trials does Northwestern University have on ClinicalTrials.gov?
Northwestern University is listed as the lead sponsor on 1,396 clinical trials in ClinicalTrials.gov, 272 of which are currently active (recruiting, enrolling, or ongoing).
How many of Northwestern University's trials are in Phase 3?
51 of Northwestern University's trials are in Phase 3, spread across 116 active drug programs.
What therapeutic areas does Northwestern University focus on?
Northwestern University's most-studied conditions on ClinicalTrials.gov are Pain, Depression, Breast Cancer, Lymphoma, Obesity.
When are Northwestern University's next clinical trial readouts?
Northwestern University has 10 upcoming primary-completion readouts tracked here; the soonest is “Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia”, expected around 2015-08-17.